Cargando…

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials

BACKGROUND: BUP-XR (a.k.a. RBP-6000 or SUBLOCADE™) is an extended-release subcutaneous buprenorphine formulation for the treatment of opioid use disorder. BUP-XR was designed to provide sustained buprenorphine exposure throughout the monthly dosing interval, at concentrations sufficient to control a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Aksana K., Ngaimisi, Eliford, Gopalakrishnan, Mathangi, Young, Malcolm A., Laffont, Celine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016750/ https://www.ncbi.nlm.nih.gov/pubmed/33135125 http://dx.doi.org/10.1007/s40262-020-00957-0

Ejemplares similares

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
por: Ling, Walter, et al.
Publicado: (2019)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
Publicado: (2020)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study
por: Larance, Briony, et al.
Publicado: (2020)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
por: Dunlop, Adrian J., et al.
Publicado: (2021)

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
por: Björnsson, Marcus, et al.
Publicado: (2023)

Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study
por: Johnson, Björn, et al.
Publicado: (2022)

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study
por: Ling, Walter, et al.
Publicado: (2019)

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
por: Frost, Michael, et al.
Publicado: (2019)

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
por: Ling, R., et al.
Publicado: (2022)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection
por: Hakomäki, Henriikka, et al.
Publicado: (2021)

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
por: Arunogiri, Shalini, et al.
Publicado: (2021)

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE)
por: Schulte, Bernd, et al.
Publicado: (2020)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
por: Maganda, Betty A, et al.
Publicado: (2015)

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY(®)) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study
por: Jones, Aksana, et al.
Publicado: (2021)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021)

Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use
por: Schreiner, Viktoria, et al.
Publicado: (2020)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine
por: D'Agnone, Oscar
Publicado: (2019)

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment
por: Lapeyre-Mestre, Maryse
Publicado: (2020)

Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia
por: Chala, Adugna, et al.
Publicado: (2023)

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence
por: Ghosh, Abhishek, et al.
Publicado: (2022)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study
por: Tay Wee Teck, Joseph, et al.
Publicado: (2021)

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
por: Gilman, Mark, et al.
Publicado: (2018)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uo99jalr6c3uht894lh8j2b9gu